ADVM stock icon

Adverum Biotechnologies

7.89 USD
+0.13
1.68%
At close Nov 12, 4:00 PM EST
1 day
1.68%
5 days
-1.62%
1 month
2.07%
3 months
21.57%
6 months
-13.96%
Year to date
-4.71%
1 year
-12.82%
5 years
-90.96%
10 years
-97.66%
 

About: Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Employees: 121

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,280% more call options, than puts

Call options by funds: $414K | Put options by funds: $30K

85% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 13

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

13% more funds holding

Funds holding: 60 [Q1] → 68 (+8) [Q2]

2.58% more ownership

Funds ownership: 86.12% [Q1] → 88.7% (+2.58%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

52% less capital invested

Capital invested by funds: $253M [Q1] → $121M (-$131M) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
27%
upside
Avg. target
$23
192%
upside
High target
$40
407%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
RBC Capital
Luca Issi
40% 1-year accuracy
21 / 53 met price target
27%upside
$10
Sector Perform
Maintained
5 Nov 2024
Truist Securities
Joon Lee
66% 1-year accuracy
31 / 47 met price target
407%upside
$40
Buy
Maintained
14 Aug 2024
HC Wainwright & Co.
Matthew Caufield
42% 1-year accuracy
18 / 43 met price target
280%upside
$30
Buy
Reiterated
13 Aug 2024
RBC Capital
Luca Issi
40% 1-year accuracy
21 / 53 met price target
52%upside
$12
Sector Perform
Maintained
13 Aug 2024

Financial journalist opinion

Based on 3 articles about ADVM published over the past 30 days

Charts implemented using Lightweight Charts™